Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F021 - Tackling Challenges in Epidermolysis Bullosa: What Does the Future Hold

Friday, February 16; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe an approach to assessing and managing newborns with suspected epidermolysis bullosa (EB)
  • Identify barriers and gaps in the delivery of health care for adolescents and adults with EB
  • Discuss and summarize new and emerging topical, molecular and cellular therapies for EB

Description

Epidermolysis Bullosa (EB) is a group of rare inherited disorders characterized by blistering and erosions. Both children and adults with EB present diagnostic and therapeutic challenges. This session will review both gaps and advances in the diagnosis and management of EB. Timely diagnosis and management in the newborn period will be discussed. Obstacles and opportunities in the realm of transition to adult care will be reviewed. A range of existing and emerging therapies will be appraised.

Disclosures

  • Bruckner, Anna Lee, MD: Amicus Therapeutics – C(H), I(Grants/Research Funding); Castle Creek Pharmaceuticals – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Fibrocell Science – I(Grants/Research Funding); Scioderm – I(Grants/Research Funding);
  • Marinkovich, M. Peter, MD: no financial relationships exist with commercial interests.
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Price, Harper, MD: AbbVie – I(Grants/Research Funding); Castle Creek Pharmaceuticals – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Scioderm – I(Grants/Research Funding);
Schedule
Friday, February 16
1:00 PM
Dr. Bruckner / Managing the newborn with suspected EB
1:30 PM
Dr. Price / Transition to adult EB care
2:00 PM
Dr. Murrell / Topical therapies for EB
2:30 PM
Dr. Marinkovich / Molecular and cellular therapies for EB
Event Details
  • Date
    Friday, February 16
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 24C
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Anna Lee Bruckner, MD, FAAD
Speakers
  • Dedee F. Murrell, MD, FAAD
  • Harper Price, MD, FAAD - Handout
  • M. Peter Marinkovich, MD, FAAD